Fourthly, UOP considers, like the Commission, that, for there to be no advantage to the IFP/Axens entity, IFP’s budget devoted to R & D carried out in collaboration with or on behalf of Axens would have to be financed by revenue earned in the market.
90 5. COMMENTS FROM THIRD PARTIES › 5.3. Comments submitted by UOP, Decision_act (EU) 2009/157
In forcesince 16 Jul 2008